设为首页收藏本站

中国病毒学论坛|我们一直在坚持!

 找回密码
 立即注册

QQ登录

只需一步,快速开始

搜索
热搜: 活动 交友 discuz
查看: 2224|回复: 5
打印 上一主题 下一主题

疫苗学《Vaccines》——6th Edition by (美)普洛特金

[复制链接]

1067

帖子

1032

学分

1万

金币

管理员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
1032
QQ
跳转到指定楼层
楼主
发表于 2015-7-25 14:07:34 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式

/ c( g9 ]2 j2 k0 n1 F2 D; j# e
Vaccines, 6th Edition

. ^5 i' o7 B7 P, aApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.+ e8 G. P8 G! @* w1 m7 k
1 V+ A; x1 @; a: }- m- `5 X: ]
http://yun.baidu.com/share/link?shareid=2079860221&uk=3810996606
) ~& K( i$ r! `: f! Q" O
3 a) C3 f& T+ R: zSECTION 1: General aspects of vaccination
5 V) L3 D$ `! Y) Y7 F- z* G. N& u1 A short history of vaccination 19 i, d4 g+ m2 o, u  e
2 Vaccine immunology 14
/ p- L) v! p5 P% _- K, u3 The vaccine industry 33
7 l6 D1 a1 u9 w0 O5 H4 Vaccine manufacturing 444 A5 f# f; j5 t& C) \
5 Evolution of adjuvants across the centuries 58
* G5 q0 [3 Z) j$ P2 p6 Vaccine additives and manufacturing residuals in the United States:
% e# P* G8 |" n7 W" Clicensed vaccines 71
6 S7 K. s* {( I$ D  |4 y, W4 v/ S1 r' M7 Passive immunization 80
* W& W) C  p! G( C+ A( j) Q4 _8 General immunization practices 888 C( a0 h( j8 S, {3 ^
SECTION 2: Licensed vaccines# {9 Z- Z" m; T: J: m% `: m, l# R# z. {
9 Adenovirus vaccines 1131 l" ]$ h9 E6 ~9 r7 ^& C  j) q
10 Anthrax vaccines 1277 {8 \( P8 d; u) o( F) _2 B
11 Cholera vaccines 141( {% q/ ^' W) Q" D
12 Diphtheria toxoid 1539 E; H4 [9 w+ T# o* h9 @
13 Haemophilus influenzae vaccines 1674 I$ W2 [7 W. g% k
14 Hepatitis A vaccines 183
9 P, W, X& O' g5 o) w6 M15 Hepatitis B vaccines 205$ }7 }6 J  m' O+ f; q
16 Human papillomavirus vaccines 235- s2 Q( D- q  ?/ w+ r
17 Inactivated influenza vaccines 2571 m' Q" r5 p) f3 p' m8 n) q& }
18 Influenza vaccine-live 294
: w1 ^! w* M* e& N4 F19 Japanese encephalitis vaccines 312
# {' [6 W+ [4 o0 y* m5 O20 Measles vaccines 352
9 Z) i* k* T5 y2 u. q21 Meningococcal vaccines 388( Q, B8 [: B2 e7 s* K7 s9 ^7 I" N9 h
22 Mumps vaccine 419" k) c9 k2 E, i$ J3 e' ^0 |
23 Pertussis vaccines . 447  }  I  @2 @  A$ G( U! z
24 Plague vaccines 493! H& N; l/ U+ F$ q- v
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504  {; k6 G) U7 N* p$ k  [* g
26 Pneumococcal polysaccharide vaccines 542
  w# d. Q0 X, e, s( M- Z- x% |5 l8 ~) @27 Poliovirus vaccine-inactivated . 573
; s" \& a4 L: I  }1 N) ?8 w' C28 Poliovirus vaccine-live 598
! V# M9 g" \( C* @0 K( U29 Rabies vaccines .646
* N8 V) b9 l4 K* Y/ L8 l6 u' \" ~& ]30 Rotavirus vaccines . 669# w- X/ Q! h9 F( U3 l- s! |
31 Rubella vaccine 6888 E+ {% i. z( \/ t8 Z2 r
32 Smallpox and vaccinia 7189 r, s5 R" K" L9 ?7 v" j1 p
33 Tetanus toxoid 746
& N2 H! o+ Y( K) P8 w34 Tick-borne encephalitis virus vaccines 773
" N0 w; N  X1 e, Z1 d2 m1 u35 Tuberculosis vaccines 789
- }3 M# Z% p. @- J, c36 Typhoid fever vaccines 812
' u" x! `+ F3 W8 h- A2 w( T( \37 Varicella vaccine 837" \6 k% ^/ ?3 O9 ^4 F: g+ i
38 Yellow fever vaccine 870
3 {% ~- U7 K* Y3 g) o39 Zoster vaccine 969
7 R+ ]$ ?* Y& X) _40 Combination vaccines 981
/ h1 b. A9 k3 z! g% Y! L+ p2 {SECTION 3: Vaccines in development and new vaccine strategies
" [6 d# c$ l9 m" G! d* i3 F41 Biodefense and special pathogen vaccines 1008
0 z" j2 u* g8 _: {; {7 J42 Therapeutic cancer vaccines 1018
( h4 [. b: |1 x7 ]" m43 Cytomegalovirus vaccines 1032
7 D3 Y# \2 q1 u' D1 u44 Dengue vaccines 1042
. k9 [' P$ V2 O) N3 V; a45 Diarrhea caused by bacteria 1052/ c  c: n6 q4 a: c: r  u
46 Ebola vaccine 1060
6 [" I% R- _' n2 L6 t; z0 O47 Epstein-Barr virus vaccines 10684 v0 c! t* u. j
48 Hepatitis C vaccines 1074
3 P$ n$ l( E/ T9 D  u$ l0 e' ]+ i49 Hepatitis E vaccines 1085
+ z4 |8 ]# W# d. F50 Herpes simplex virus vaccines 10901 P- T* c" o8 [/ B5 A  b/ n8 z
51 Human immunodeficiency virus vaccines 1097
- m5 ^8 Q9 V' N% `  t8 b: p52 Lyme disease vaccines 1122
: u4 o+ @) h6 J0 {0 Y1 U8 `53 Malaria vaccines 11337 M) F: m: R3 g2 Y
54 Noninfectious disease vaccines 1138
+ l0 I' p* u7 a" [55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
% l  J* R% r9 I! ^  Y8 v* ]56 Parasitic disease vaccines 1154& X2 D( c0 k$ T1 m. I! m, P) V
57 Staphylococcus aureus vaccines 1161
( x3 p' y: m/ e+ d- q2 @: h6 }58 Streptococcus group A vaccines 1169
0 ~( _1 Y6 H1 `5 W1 @* o! g  o$ K+ @/ Y59 Streptococcus group B vaccines 1176
' W: O. o3 U  A, O8 t, |4 i60 Technologies for making new vaccines 1182
, T4 x) e3 I- T5 |' `5 j/ U61 Alternative vaccine delivery methods 1200/ q3 T; }2 W5 P' T
62 The development of gene-based vectors for immunization 1232& |5 q( t7 W+ e, H/ W! `0 h5 |
SECTION 4: Vaccination of special groups
0 ]# Z- N  k4 x63 Vaccination of immunocompromised hosts 1243
5 w0 @/ |5 ^( o$ ~5 S* b64 Vaccination of human immunodeficiency virus-infected persons 1257
4 W: R1 T7 R6 z) N" D65 Vaccines for international travel 1270
5 x9 E: C$ e( c4 b  F66 Vaccines for health care personnel 12909 O; y* t% Q5 G7 u; f
SECTION 5: Public health and regulatory issues7 _: t8 e% r: h7 x/ D: K8 |. ?/ S* X
67 Immunization in the United States 1310+ |, z4 V6 @( k1 A
68 Immunization in Europe . 13349 V7 m% _6 [8 T/ Q& D
69 Immunization in the Asia-Pacific region 1353
$ G4 `- N0 `# M, d70 Immunization in developing countries 13690 o! t1 P7 h4 {" f) ?' A
71 Community immunity 1395
; `: L+ {3 J7 h( |, y2 t/ Z% K7 M6 W72 Economic analyses of vaccine policies 1413* l: `: a" V- |5 Q# H
73 Regulation and testing of vaccines 1427
# g1 Y" m. i. B. ?74 Regulation of vaccines in Europe 1447
- u3 u. v' @: r5 V8 h& b- E75 Regulation of vaccines in developing countries 1454! ^, X+ P% f8 H. V- @
76 Vaccine safety 1464
; n6 n9 X' `+ o3 s2 s77 Legal issues . 1481
$ k- B) M( t' F9 O& n; n; i, R78 Ethics 1508& V9 {2 z% `7 T4 t4 `* c$ B  I

6 c  g. @, i4 T" S. R
; S3 V# ]4 I$ ?: C7 [- l3 h
) U9 ~- U: l: s: @

6 ]+ R* A& F, Q0 a& h2 v) J' k
分享到:  QQ好友和群QQ好友和群 QQ空间QQ空间 腾讯微博腾讯微博 腾讯朋友腾讯朋友
收藏收藏 分享分享 支持支持 反对反对

7

帖子

2

学分

357

金币

病毒学院小学生

Rank: 2Rank: 2

积分
2
沙发
发表于 2015-7-26 14:55:58 | 只看该作者
非常感谢

36

帖子

27

学分

3544

金币

病毒学院中学生

Rank: 3Rank: 3Rank: 3

积分
27
板凳
发表于 2015-8-13 17:54:21 | 只看该作者
谢谢分享

36

帖子

27

学分

3544

金币

病毒学院中学生

Rank: 3Rank: 3Rank: 3

积分
27
地板
发表于 2015-8-13 17:55:46 | 只看该作者
怎么看不到相关下载呀

1067

帖子

1032

学分

1万

金币

管理员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
1032
QQ
5#
 楼主| 发表于 2015-8-13 21:26:48 | 只看该作者

" ?1 J" [/ a9 @Vaccines, 6th Edition1 K3 _5 ]/ i1 U. N: T# L

4 T0 p& p- i2 W& q# VApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.
, j4 U" u2 ]+ E/ M7 Q
3 e) k2 T3 Y( L9 X# t8 Ehttp://yun.baidu.com/share/link? ... 1&uk=3810996606
, T5 ~/ n2 {9 J5 ~( r
' Q9 D4 r) S: Y8 f2 KSECTION 1: General aspects of vaccination
8 {9 {6 d( C% p& u+ ]3 {1 A short history of vaccination 1
7 o& J  W* h6 R% Q: g7 m2 Vaccine immunology 14! V+ [( g! g' J6 x& s0 t% V, K
3 The vaccine industry 334 |2 q% v" t0 h7 Z9 Q( E: |* Z5 _
4 Vaccine manufacturing 44
, v8 ]9 M: q) ~5 Evolution of adjuvants across the centuries 58
  Q* S* w# ]3 J: \: O$ `( r) e- j6 Vaccine additives and manufacturing residuals in the United States:
/ |, M( j) D3 y0 ^3 f0 W& B( ylicensed vaccines 71- p: v. F. T$ t
7 Passive immunization 801 F( \. L  n( c; v$ _3 z2 |$ G
8 General immunization practices 88
' t9 E  |1 u9 D5 t. g2 [3 a( TSECTION 2: Licensed vaccines# o1 d, F: A4 }. M) B& W" ~
9 Adenovirus vaccines 113
" x9 l4 @$ t' |10 Anthrax vaccines 1274 L. j& ?" n7 R3 p& q4 v& w
11 Cholera vaccines 141
+ _: S- O8 \7 D$ M) D/ C& `8 R# a12 Diphtheria toxoid 1538 g" t; k  V- S/ x7 v. Y) u; m
13 Haemophilus influenzae vaccines 167
9 b6 n; J6 T7 P% f% Z14 Hepatitis A vaccines 183* a- ]% Q5 f- R) u' Z; L
15 Hepatitis B vaccines 2058 A0 d7 U6 }1 W1 E
16 Human papillomavirus vaccines 235- j& ^% ^) |9 F7 g- r9 T
17 Inactivated influenza vaccines 2570 Z' x, G6 ^, o% T$ V2 T
18 Influenza vaccine-live 294  L( m/ X' Y5 s( X
19 Japanese encephalitis vaccines 312
( p- w. S. J1 S+ X$ I20 Measles vaccines 3525 X2 P8 K  p4 P  o$ @
21 Meningococcal vaccines 3881 @  f8 c( g. v1 L
22 Mumps vaccine 419
; ~) M  |9 l3 D7 U! ]8 I: b23 Pertussis vaccines . 447' I" v+ o. p1 u2 U) {/ Q% u% q: \
24 Plague vaccines 493
. e4 \+ x. r, h$ m25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504$ N5 L5 z& `9 e1 N3 H% W4 v+ d) R+ B
26 Pneumococcal polysaccharide vaccines 5429 m- r* Z8 w! c
27 Poliovirus vaccine-inactivated . 573
" o& E, F/ d9 C6 Q28 Poliovirus vaccine-live 598
- [% x) K. a  q) |) v8 s! O' x( Z29 Rabies vaccines .646
$ v5 a! S& \7 p30 Rotavirus vaccines . 669
, W! I' ^9 g2 ?+ t+ G2 W% d31 Rubella vaccine 688
4 n6 o2 v: ~2 F% \32 Smallpox and vaccinia 718
& ^/ \# c1 |: O5 R- y2 w% z' T$ [33 Tetanus toxoid 746- L$ f7 Z/ @! }1 {) E
34 Tick-borne encephalitis virus vaccines 773
# C9 }' u0 w: B3 M7 R  d: f35 Tuberculosis vaccines 7898 A  F0 s* l" H% }! P" v6 a6 u
36 Typhoid fever vaccines 812% o) v8 ^! e5 }  ]) L7 v* s
37 Varicella vaccine 837
. _& n2 X- ?4 h1 Z38 Yellow fever vaccine 870
0 P( p) G7 Q& P4 a39 Zoster vaccine 969
$ K2 w" e: n' v8 _4 Q! M, |4 |! r40 Combination vaccines 981+ o  B4 ~% m! \) M* w7 ^! G
SECTION 3: Vaccines in development and new vaccine strategies: ]/ `& b$ @" A
41 Biodefense and special pathogen vaccines 1008
) B0 W# ]8 D- j; p" D1 }5 L42 Therapeutic cancer vaccines 1018) L. V& j+ P) f' W$ o7 K8 @
43 Cytomegalovirus vaccines 1032
- _/ w( N/ O7 \1 p44 Dengue vaccines 1042
% M! x( X# Z! Q# \, A! o' d45 Diarrhea caused by bacteria 1052
4 _/ h1 P* ~  K$ g% e% X/ O/ R46 Ebola vaccine 10608 ]4 S8 e1 {8 w9 A- P4 O; \7 H; [
47 Epstein-Barr virus vaccines 1068
0 I2 l8 x$ O7 y48 Hepatitis C vaccines 10741 o) f& l5 x3 w( m: Z4 {1 Y, d
49 Hepatitis E vaccines 1085
4 u' d& K% }3 x+ b50 Herpes simplex virus vaccines 1090% P$ [. _: U2 b2 J
51 Human immunodeficiency virus vaccines 1097; H7 x+ _3 Y& Q1 K+ D, Y
52 Lyme disease vaccines 1122( ?( r8 J( u& M) E' G2 Q
53 Malaria vaccines 1133
5 e6 t0 `0 `3 O% E& _54 Noninfectious disease vaccines 1138
/ E9 z4 x! c& ^  M. j55 Respiratory syncytial virus and parainfluenza virus vaccines 1146% q" S, B$ b( E$ U3 O+ E
56 Parasitic disease vaccines 1154
8 T: H4 }+ b; O$ v- a57 Staphylococcus aureus vaccines 1161
7 g2 t7 i) U' j9 D$ z1 _: X58 Streptococcus group A vaccines 1169& I8 F+ K9 Y- t- e. g9 M
59 Streptococcus group B vaccines 1176
0 c- g( [$ I. J4 M* T1 m$ s60 Technologies for making new vaccines 1182
7 {# l" D) Z9 l6 T, F. R; y1 u" ~61 Alternative vaccine delivery methods 1200
+ u1 X: Q$ \; v62 The development of gene-based vectors for immunization 12320 G8 ~  |  h* @: G0 k1 |
SECTION 4: Vaccination of special groups( q4 l5 _; n+ `$ S7 {) g' N+ O" x
63 Vaccination of immunocompromised hosts 1243
( o" x& w' i* V+ F* T3 b, w64 Vaccination of human immunodeficiency virus-infected persons 1257' n% f2 a% d- t
65 Vaccines for international travel 1270$ Z! D: e: Y, \& C$ J
66 Vaccines for health care personnel 1290
: P% m/ S0 z  ]& N; i9 ^SECTION 5: Public health and regulatory issues4 ]2 l: D, k3 j
67 Immunization in the United States 1310
) C+ T4 |: R2 F- n/ \68 Immunization in Europe . 1334
, T& k: l" U# @& V# E69 Immunization in the Asia-Pacific region 1353' C, v2 X5 l; W2 `6 [
70 Immunization in developing countries 1369
) y" c* X( y, B" m$ V  E4 U+ a71 Community immunity 1395, X6 X* q) a% i, M9 L/ N% n
72 Economic analyses of vaccine policies 1413# \5 F6 k! a- V) N& J
73 Regulation and testing of vaccines 14273 ?$ {+ n+ q3 A
74 Regulation of vaccines in Europe 14470 v+ I: G, C! U! E0 M9 g
75 Regulation of vaccines in developing countries 1454
' c5 ]/ j. B- V8 P76 Vaccine safety 1464+ `  i- k) c4 B* }0 I
77 Legal issues . 14819 v6 W; x5 U: I
78 Ethics 1508+ [" p6 P# O1 s, H4 L. l+ B; ~; N2 w

' O0 E9 b6 }+ R& a- W; }; r& h, @4 `( B

23

帖子

39

学分

5741

金币

病毒学院中学生

Rank: 3Rank: 3Rank: 3

积分
39
6#
发表于 2017-5-2 15:25:27 | 只看该作者
Vaccines, 6e, 2012% o) J' d* x! [- y+ {" L
% c. f1 {8 K6 c4 D: Z- Z/ E
Hardcover: 1570 pages5 A2 x8 @+ J" F
Publisher: Saunders; 6 edition (October 30, 2012)  j- ]# j  \9 A1 p( t3 q: h
Language: English3 F. _. \/ g4 X' O8 g* ?/ d9 n* Y1 V; ^3 G
ISBN-10: 14557009085 l) t0 e/ c0 V: C# Z. f4 r3 I
Size: 52.3mb (original pdf)
9 \( Z( Z. h7 r9 g6 m$ |% l' c& E: l& c9 `  C  X) x
2013 BMA Medical Book Awards Highly Commended in Public Health!
  i( {2 k7 x+ @- b% d" [Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice!
" a( b7 n8 O+ O2 L" c) G% R. U
- n1 q+ k' h$ I# Q3 d" tGain a complete understanding of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
  ?3 D% }) C# j, E3 [, N+ d0 oUpdate your knowledge of both existing vaccines and vaccines currently in the research and development stage.7 F5 Y9 y  ~2 ]! @: l
Get complete answers on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
, I( P/ V% }; e  s3 @: D! t5 UAnalyze the cost-benefit and cost-effectiveness of different vaccine options.7 [7 l1 d2 i$ ~% D# H
Clearly visualize concepts and objective data through an abundance of tables and figures.% ]  C4 K& z, X' n# c0 h& S
Perform seamless searches of the complete text online, access all the references, and download all the images at www.expertconsult.com.$ k  w4 }; v" G1 d. w5 P( `6 g$ ?! c4 ^/ f
Make optimal use of the latest vaccines for pneumococcal disease, rotavirus, human papillomavirus, herpes zoster, meningococcal disease, and much more.
; o# y) |6 J# x# gStay at the forefront of new developments with completely updated chapters on malaria and HIV vaccines, a new chapter on vaccine regulations across the world, and many other revisions throughout.
  Y7 K5 B, N( v4 D2 I5 j0 G
, O( ]& L8 Z2 w# E9 k/ zDownload link: http://pan.baidu.com/s/1i5NxwLR * F+ u; S1 d! J" _) Q3 P$ W
Code for downloading: dv96
: W6 }3 n4 K' f2 U4 o" X9 V; D
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|论坛App下载|Archiver|小黑屋|中国病毒学论坛    

GMT+8, 2024-11-23 10:18 , Processed in 0.120112 second(s), 28 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表